Search alternatives:
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
side decrease » sizes decrease (Expand Search), fid decreased (Expand Search), step decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
side decrease » sizes decrease (Expand Search), fid decreased (Expand Search), step decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
-
2401
-
2402
Vitamin D3, but not the Cisplatin, could moderately reduce STZ-induced hyperglycemia in mice (a) Schematic representation of experimental protocol followed in the study: After accl...
Published 2025“…Beginning from day 28, when the solid tumors are of ~100mm<sup>3</sup> size, control and experimental mice were administered with drugs every other day for 18 days (total duration 46 days); on day 46, the mice were sacrificed and blood, vital organs and tumors were harvested for further analysis (b) Administration of STZ increased fasting blood sugar in mice: In order to establish hyperglycaemic state, mice were administered with low-dose STZ as detailed in methods section and blood sugar content determined using Morepen glucose monitoring strips. The data showed a significant increase in fasting blood glucose (FBG) beginning from day 6. …”
-
2403
Line graph showing the values of inflammatory cytokines at baseline and after treatment.
Published 2025Subjects: -
2404
-
2405
-
2406
Heatmap and pathway analysis of the potential metabolites in colon tissue related with diarrhea.
Published 2025Subjects: -
2407
-
2408
-
2409
-
2410
-
2411
-
2412
-
2413
Baseline and Post-Treatment Results of Echocardiographic Variables in Each Experimental Group.
Published 2025Subjects: -
2414
Baseline and Post-Treatment Serum Cytokine Levels in Each Investigational Group.
Published 2025Subjects: -
2415
-
2416
Baseline and Post-Treatment Serum Levels of NT-proBNP in Each Investigational Group.
Published 2025Subjects: -
2417
Variables obtained from the SF-36 quality of life questionnaire in each experimental group.
Published 2025Subjects: -
2418
-
2419
-
2420
The importance of entry criteria from the point of view of the SD method ‐ combination A.
Published 2024Subjects: